Ascendis Health Limited

JSE:ASC Stock Report

Market Cap: R563.2m

Ascendis Health Past Earnings Performance

Past criteria checks 2/6

Ascendis Health has been growing earnings at an average annual rate of 41.5%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been declining at an average rate of 30.3% per year. Ascendis Health's return on equity is 6.7%, and it has net margins of 2.8%.

Key information

41.5%

Earnings growth rate

42.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate-30.3%
Return on equity6.7%
Net Margin2.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

There Is A Reason Ascendis Health Limited's (JSE:ASC) Price Is Undemanding

Sep 23
There Is A Reason Ascendis Health Limited's (JSE:ASC) Price Is Undemanding

Revenue & Expenses Breakdown

How Ascendis Health makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

JSE:ASC Revenue, expenses and earnings (ZAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,472424620
31 Mar 241,484-45200
31 Dec 231,496-516290
30 Sep 231,516-1686320
30 Jun 231,535-2865830
31 Mar 231,547-2775720
31 Dec 221,559-2685600
30 Sep 221,559-5135920
30 Jun 221,559-7596240
31 Mar 221,833-1,2117400
31 Dec 212,107-1,6638560
30 Sep 211,966-1,6777980
30 Jun 211,825-1,6917410
31 Mar 21761-1,9853520
31 Dec 20-304-2,280-360
30 Sep 20949-1,8963470
30 Jun 202,203-1,5127300
31 Mar 205,761-1,3721,7120
31 Dec 195,417-1,8841,6850
30 Sep 195,644-1,8361,7130
30 Jun 195,872-1,7881,7400
31 Mar 195,494-9121,7320
31 Dec 185,116-361,7240
30 Sep 185,313-11,7210
30 Jun 185,511341,7170
31 Dec 177,1524061,7800
30 Sep 176,7803731,6940
30 Jun 176,4093401,6090
31 Dec 165,1542041,3430
30 Sep 164,5341811,1870
30 Jun 163,9141591,0300
31 Mar 163,6362049550
31 Dec 153,3542539020
30 Sep 153,0852318480
30 Jun 152,8172107940
31 Dec 142,2891717370
30 Sep 141,9541546430
30 Jun 141,6181365500
31 Dec 13950683030

Quality Earnings: ASC has a large one-off gain of ZAR38.8M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: ASC became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ASC has become profitable over the past 5 years, growing earnings by 41.5% per year.

Accelerating Growth: ASC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ASC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.7%).

Return on Equity

High ROE: ASC's Return on Equity (6.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascendis Health Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marcelle JankelowInvestec Bank Limited (SA)
Marcelle JankelowInvestec Bank plc (UK)